Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kiromic BioPharma Inc
KRBP | US
19.80
USD0.02
0.13%
KRBP | US
Loading StockChartView...
About Kiromic BioPharma Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
13/04/2026
Close
19.80
Open
20.11
High
20.12
Low
19.80
Kiromic BioPharma Inc. an artificial intelligence driven allogeneic cell therapy company engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1 an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1 an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings Inc. and Longwood University as well as a research and development collaboration agreement with Molipharma S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic Inc. and changed its name to Kiromic BioPharma Inc. in December 2019. Kiromic BioPharma Inc. was founded in 2006 and is headquartered in Houston Texas.
View LessKRBP | US
Risk
0.0
Sharpe
13.07
Luna's Score
57/100
Recommendation
Hold
Luna says (KRBP | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
0.0%1 month
0.0%3 months
0.0%6 months
0.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
11.55
Debt to equity
-2.59
Debt to assets
1.07
Ent. to EBITDA
-0.13
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-20.11M
MarketCap
30.60M
MarketCap(USD)
30.60M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-1.13K
Short ratio
1.45
Short perc.
6.82
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.70
Range1M
0.70
Range3M
0.70
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.23
Price X volume
237.54
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.13 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 11.55 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | - | 72.80 | - |
| Debt to Equity | -2.59 | -1.23 | Cheaper |
| Debt to Assets | 1.07 | 0.25 | Expensive |
| Market Cap | 30.60M | 3.66B | Emerging |
